Breast Cancer Treatment Based on Organ-like Culture

Xijing Hospital300 enrolled

Overview

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Breast Cancer Organoids

Interventions

TrastuzumabDRUG

Trastuzumab Injection

Doxorubicin HydrochlorideDRUG

Doxorubicin Hydrochloride Injection

Epirubicin hydrochlorideDRUG

Epirubicin hydrochloride injection

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form Exclusion Criteria: Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study. Other investigators believe that patients who are not suitable for this study group

Locations (1)

JingSu

Xi'an, Shaanxi, China

Outcomes

Primary Outcomes

Detection of cell viability

1\. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration.

Time frame: 8 weeks before neoadjuvant chemotherapy

Secondary Outcomes

Detection of in vitro model drug sensitivity

2\. In vitro model drug sensitivity: sensitive and insensitive

Time frame: 8 weeks before neoadjuvant chemotherapy

Clinical efficacy assessment according to RECIST criteria

Clinical efficacy evaluation according to RECIST criteria: imaging ultrasonography, histological pathology.

Time frame: 8 weeks before neoadjuvant chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.